STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

ITCI INTRA CELLULAR THERAPIES INCORPORATED StockScouter® Report

4

StockScouter® Score

INTRA CELLULAR THERAPIES INCORPORATED, a small cap company in the healthcare sector, is expected to slightly underperform the market over the next six months with higher than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • The most recent quarterly earnings report higher than analysts’ consensus forecast. Positive
  • The 50-day moving average for ITCI is significantly above its 200-day moving average. Positive

 

Concerns

  • Earnings growth in the past year has decelerated rapidly compared to earnings growth in the past three years. Negative
  • Two or more executives, board directors or major shareholders – including one high-level executive -- sold a large number of shares recently. Very negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that small cap stocks will be neutral, stocks will be , and healthcare stocks will be neutral.

Expected Risk/Return

Progress: 100% done.
Progress: 40% done.
Low
High

Core Model Grades

B
F
N/A
B

Previous Ratings

4
4
4